Original Article
SF6 Assisted Pneumatic Vitreolysis in
Cases of Vitreomacular Traction Syndrome
Rana Muhammad Mohsin Javed, Asad
Aslam Khan, Haroon Tayyab, Nasir Chaudhry
Pak J Ophthalmol 2018, Vol. 34, No. 3
. . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
See end of article for authors affiliations
..
.. Correspondence to: Haroon
Tayyab Eye
unit-III, Institute of Ophthalmology, King Edward Medical University, Mayo
Hospital, Lahore Email: haroontayyab79@googlemail.com |
Purpose:
To evaluate the efficacy of Intravitreal expansile sulfur
hexafluoride gas injection (SF6) for the treatment of symptomatic
vitreomacular traction (VMT) syndrome. Study
Design: Prospective interventional study. Place
and Duration of Study: Eye unit-III, Institute of Ophthalmology,
King Edward Medical University, Mayo Hospital Lahore. Study was conducted
from September 2017 to February 2018. Material
and Methods: A total of 21 eyes were included in the
study who presented with VMT diagnosed on
optical coherence tomography findings including patients whose VMT was associated with
epiretinal membrane and VMT in patients of
Diabetic Retinopathy. Symptomatic patients with VMT were offered the option
of intravitreal SF6 injection. Patients were included in this study after
meeting specific inclusion and exclusion criteria. Results:
Total 21 patients were included in this
study. Mean age was 57.80 ± 10.77 years. Mean value for pre injection mean
foveal thickness was 506.33 ± 192.37 and post injection mean foveal thickness
was 383.61 ± 270.37. Significant decreases in post injection mean foveal thickness
was seen in patients (p-value = 0.053). After 1st week follow up
VMT release was seen in only 3 (14.3%) patients and at 1st month
follow up VMT release was seen in 9 (42.9%) patients. Conclusion:
Intravitreal
SF6 gas injection is safe, cheaper and effective alternative for VMT
treatment in terms of better results when compared with intravitreal
ocriplasmin. Although its efficacy is not comparable with vitrectomy. Key Words: Vitreomacular
traction, Sulfur hexafluoride, Macula, Ocriplasmin, Vitrectomy. |
In 1970, Reese et al reported an
uncommon condition of macula in which traction on macula was associated by an
incomplete detachment of posterior vitreous and escorted by low visual acuity1. This condition
was confirmed with the help of histological studies because at that time
imaging studies were not possible due to unavailability of OCT. Later on this
condition was termed as vitreomacular traction (VMT) syndrome. As primarily
described in typical form of VMT syndrome, throughout the peripheral fundus the
vitreous is separated from the retina but remains adherent to macular area posteriorly,
causing anteroposterior traction on macula2.
In general population,
prevalence of isolated idiopathic VMT without macular hole has been estimated
around 22.5 cases per 100,000 patients with an incidence rate of 0.6 per
100,000 persons years3. As per findings
of epidemiological studies the age range of VMT patients ranges in between
48-64 year with a mean age around 56-70 years with higher prevalence among
females4.
Patients with vitreomacular
traction (VMT) may possibly suffer from compromised
sight-related issues, emotional impact and physical restrictions5. The impact of vitreomacular
traction and macular hole can affect daily living activities, lifestyle,
and quality of life5. Patients can experience
irreversible vision loss and progressive sight-threatening symptoms due to
vitreomacular traction2,6,7. Research
has shown that in only around 10% of people, VMT resolves spontaneously8. In cases where
VMT does not resolve spontaneously, patients may experience anatomical damage
and further visual impairment2. More recently, based on reports of landmark clinical
trials9,10 intravitreal ocriplasmin injection was approved in October 2012
for use in patients with VMT syndrome. Pharmacologic vitreolysis with
ocriplasmin injection is less invasive than vitrectomy but has been reported in
premarketing and postmarketing experiences to cause transient visual loss, lens
subluxation, electroretinogram changes, ellipsoid zone changes, retinal breaks
and dyschromatopsias11-13.
In (MIVI-TRUST) trial, it was
reported that ocriplasmin resulted in improved
visual outcome as reported by patients as compared to placebo14. In addition,
although a randomized controlled trial demonstrated that the rate of release of
VMT after intravitreal ocriplasmin injection was significantly higher than
placebo (26.5 vs. 10.1% at 28 days), this success rate is much lower than that
seen with vitrectomy15. Intravitreal
Sulfurhexaflouride (SF6) injection provides a less invasive and lower cost
alternative to vitrectomy for symptomatic VMT syndrome. Although vitrectomy is
very successful in releasing VMT, there are risks of endophthalmitis, cataract,
and retinal tear and detachment16. In contrast,
intravitreal gas injection safety profile is well recognized over many decades
of use in the repair of retinal detachments, and SF6 gas is readily available
in most retina practices17.
VMT was defined by OCT findings
of: vitreous attachment to within 3 mm diameter of fovea with peri-foveal
detachment accompanied by foveal structural distortion; foveal detachment from
RPE; and no full thickness foveal defect.
Rationale
for this study was to determine the efficacy of intravitreal expansile sulfur
hexafluoride gas injection (SF6) for the management of symptomatic
VMT. Although traditional management of VMT is with vitrectomy, this can be invasive
and costly; however use of SF6 is injection provides a lower cost
alternative to vitrectomy for symptomatic VMT syndrome. So far, no local study
has been conducted that evaluates the role of SF6 in management of VMT. Results
of this study may provide support for the future clinical use of SF6 to treat
VMT in our population.
MATERIAL
AND METHODS
This
prospective interventional study was performed from September
2017 to February 2018 for a duration of 6 months in Eye Unit-III of Mayo
Hospital Lahore. Approval from hospital ethical committee
was sought before commencing this study. Patients were selected from OPD of Eye
Unit-III, Mayo Hospital Lahore after informed consent non-randomized purposive
sampling. All patients underwent baseline best corrected visual acuity (BCVA),
tonometry, complete slit lamp examination and spectral domain OCT (SD-OCT).
Symptomatic patients with VMT were offered the option of intravitreal SF6
injection. The patients were included and excluded after meeting the following
criteria:
Inclusion Criteria was, patients
with age >18 presenting with VMT as
defined by clinical and SD-OCT findings. Clinical Findings included metamorphopsia or
decreased BCVA (<20/25).
SD-OCT findings included posterior vitreous
adherent within a 1,500 ΅m radius of the foveal center leading to vitreofoveal
traction plus microstructural retinal changes with history of more than one
month. VMT associated with epiretinal membrane (ERM) and VMT in patients of
Diabetic Retinopathy were included in the study.
: Following patients were excluded from the study; pseudophakia with
posterior capsular rent, any macular hole, subluxated IOL and crystalline lens,
macular degeneration, retinal vascular occlusion, aphakia, high myopia (> -8
dioptres), uncontrolled glaucoma, vitreous opacification, retinal tear or
retinal detachment, vitrectomy surgery and macular laser.
Intravitreal injections were
performed in the operation theater of Eye Unit-III with the use of topical
anesthetic, lid speculum, and povidoneiodine preparation. 0.3 ml of 100% SF6
gas was injected under visualization of microscope through the pars plana in a
30-gauge needle.No positioning was required after the
injection except in phakic patients who were
advised to avoid supine position to prevent gas induced cataract formation. Patients
were evaluated 01 week and 01 month after the injection with full examination
and spectral domain optical coherence tomography.
We used
IBM SPSS 23 for data analysis. Quantitative data (Age, HVMA, MFT & VA) was
presented by using mean ± SD. Qualitative
data (Gender, side of eye, lens
status, release of VMT & Side effects) was presented by using frequency
table and percentages. Pre and post injection VA was compared with the help of
paired sample test (if data fulfilled the assumption of normality)/ Wilcoxon
Signed Rank Test. p-value <0.05 was taken as significant.
RESULTS:
A total
of 21 eyes were included in this study. Mean age of patients was 57.80 ± 10.77
years. Age of the patients ranged between 40-70 years. Among patients 3 (14.3%)
were males and 18 (85.7%) were females. Male to female
ratio was 1:6. Mean duration of symptoms of patients was 3.14 ± 1.27.
There were 17 (80.95%) patients whose right eye was
injected and the remaining 4 (19.05%) patients left eye was injected. 14 (66.67%) patients were phakic and 07 (66.67%)
patients were pseudophakic. Pre injection and post injection BCVA
is shown in Table 1. Mean value for pre-MFT was 506.33 ± 192.37
and post-MFT was 383.61 ± 270.37 (Table 2).
Significant decrease in post injection MFT was seen in patients (p-value = 0.053).
After 1st week follow up VMT release was seen in only 3 (14.3%) patients
and at 1st month follow up VMT release was seen in 9 (42.9%)
patients (Table 3). During follow up time period none of the patients presented
with any side effects. The pre and post intervention OCT results of 3 patients
are shown in Figure 1, 2 and 3.
Table -1: Visual Acuity
of patients pre & post injection (1st week and 1st
month).
Visual Acuity |
Pre-Injection |
Post Injection 1st
Week |
VA (1st
Month) Post Injection |
|
6/18 |
1 |
- |
3/60 |
3 |
6/36 |
5 |
- |
6/12 |
3 |
6/60 |
4 |
- |
6/18 |
3 |
CF 1 feet |
9 |
6 |
6/24 |
2 |
CF 1 Meter |
2 |
- |
6/36 |
3 |
CF 2 Meter |
0 |
3 |
6/9 |
1 |
Total |
21 |
9 |
CF 1 meter |
3 |
|
CF 2 1 meter |
3 |
||
Total |
21 |
Table- 2: Pre & Post
Injection MFT .
Pre-MFT |
Post MFT |
|
N |
21 |
21 |
Mean |
506.33 |
383.61 |
SD |
192.37 |
270.37 |
Min |
299 |
168 |
Max |
762 |
905 |
Wilcoxon Signed Rank
Test= -1.932, p-value=0.053 |
Table -3: VMT Release
& Side effects .
VMT Release |
Side Effects |
|
n=21 |
n=21 |
|
1st Week Post-injection
|
3 (14.3%) |
0 (0%) |
1st Month Post-injection |
9 (42.9%) |
0 (0%) |
Fig. 1: Pre SF6 injection and post one month of injection release of
VMT.
Fig. 2: Pre SF6 injection and post one month of injection release of VMT
but failure of full thickness macular closure.
Fig. 3: Pre SF6 injection and post one month of injection failure of
release of VMT.
DISCUSSION:
Results of this study report
the efficacy of intravitreal expansile sulfur
hexafluoride gas injection (SF6) for the treatment of symptomatic
VMT syndrome. VMT was released in 14.3% patients within 1st week
after the injection and at 1st month VMT was released in 42.9%
patients. None of the patients suffered any side effects after the injection at
1st week and 1st month follow up. A significant
difference was seen in MFT after injection. i.e. Pre-MFT: 506.33 &
Post-MFT: 383.61, p-value = 0.053. No local
study is published yet in which efficacy of intravitreal expansile sulfur
hexafluoride gas injection (SF6) was determined for the treatment of
symptomatic VMT syndrome.
Day et al in his
retrospective study treated symptomatic VMT syndrome patients with pure 0.3ml
intravitreal SF6. VMT was released in 55.6% of the patients on SD-OCT at one
month. Significant reduction was seen in mean central subfield thickness and
significant change was seen in VA18. Mori et al, in
his case series achieved 95% complete PVD after a single intravitreal SF6
injection in eyes with a stage II macular hole19. Steinle N in his
study reported the VMT release among 113 patients by using 3 treatment
modalities. i.e. intravitreal ocriplasmin (54 patients), C3F8 gas injection (32
patients), and SF6 gas injections (27 patients). VMT release with C3F8 was
achieved in 84% patients, with SF6 it was 56% and with intravitreal ocriplasmin
it was 48% respectively20. Results
of this study are consistent with the findings of Day
et al, Mori and Steinle N in terms of VMT release. However in
this study none of the patients suffered any kind of side effects.
MG Claus in his study reported
the release of VMT after 19 days of intravitreal injection of SF6 gas21. The main advantage of using SF6 gas
are its shorter duration as compared to the average duration of C3F8 which is
38 days22. The shorter duration
of SF6 allows early resumption of normal activities and travel as well as it
may reduce unwanted vitreoretinal traction that may result into retinal breaks.
Although success rate for inducing a PVD is higher with C3F8
gas as compared to SF6 gas. Keeping this point in mind duration is much more
important factor than the size of a gas bubble which promotes liquefaction of
vitreous followed by VMT release23.
There are different
kinds of gases which can be used as an option for treating VMT. Intravitreal air does not expand and lasts less than 1 week. Size of SF6 gas doubles the original
volume injected and it can last for 20 days. However C3F8 gas quadruples its
initial volume and it lasts for >2 months in the eye. Using shorter acting bubble of gas has its own advantages
(inferior scotoma symptoms with shorter duration, short altitude restrictions
duration, lower cataract chances in phakic patients, minor expansion and fewer
IOP concerns). But shorter acting gas bubble is not as much effective as C3F8
for the release of VMT24.
If the use of pneumatic vitreolysis is proven safe and effective, it has protean
advantages. Injection of gas is cost
effective, readily available, needs no detailed and special preparations unlike
vitrectomy25.
CONCLUSION
Intravitreal SF6 gas
injection is a safe, cheaper and effective alternative for the treatment of VMT
in terms of better results when compared with intravitreal ocriplasmin. When
compared to vitrectomy, it has lower success rates.
Conflict of Interest
:None to disclose.
Authors Affiliation
Dr.
Rana Muhammad Mohsin Javed
MBBS,
FCPS, VR Fellow
Eye
Unit III, Institute of ophthalmology, King Edward Medical University, Mayo
Hospital Lahore
Prof.
Asad Aslam Khan
MBBS,
MS, FCPS, PhD
Eye
Unit III, Institute of ophthalmology, King Edward Medical University, Mayo
Hospital Lahore
Dr.
Haroon Tayyab
MBBS,
FCPS, FCPS (VRO), FICO
Eye
Unit III, Institute of ophthalmology, King Edward Medical University, Mayo
Hospital Lahore
Dr.
Nasir Chaudhry
MBBS,
FCPS, Fellowship VR
Eye
Unit III, Institute of ophthalmology, King Edward Medical University, Mayo
Hospital Lahore
Role of Authors
Dr. Rana Muhammad
Mohsin Javed
Primary
Surgeon, Literature search.
Prof. Asad Aslam
Khan
Study
Concept, Design.
Dr. Haroon Tayyab,
Literature
search, Data analysis
Dr. Nasir Chaudhry
Manuscript
write up
REFERENCES
1.
Reese AB, Jones IS, Cooper WC. Vitreomacular
traction syndrome confirmed histologically. Am J Ophthalmol.
1970 Jun; 69 (6): 975-7.
2. Bottσs J, Elizalde J, Arevalo JF, Rodrigues EB, Maia M.
Vitreomacular traction syndrome.
J Ophthalmic Vis
Res. 2012
Apr; 7 (2): 148-61.
3. Jackson TL, Nicod E, Simpson A, Angelis A, Grimaccia F, Kanavos P. Symptomatic vitreomacular adhesion. Retina. 2013 Sep; 33 (8): 1503-11.
4. Steel DH, Lotery AJ. Idiopathic
vitreomacular traction and macular hole: a comprehensive review of
pathophysiology, diagnosis, and treatment. Eye (Lond). 2013 Oct; 27 Suppl. 1: S1-21.
5. Okamoto F, Okamoto Y, Fukuda S, Hiraoka T, Oshika T. Vision-related quality of life and visual function after vitrectomy for
various vitreoretinal disorders. Invest Ophthalmol Vis Sci. 2010 Feb; 51 (2): 744-51.
6. Carpineto P,
Di Antonio L, Aharrh-Gnama A, Ciciarelli V, Mastropasqua L. Diagnosing and treating vitreomacular adhesion.
Eur Ophthalmic Rev. 2011; 5 (1): 69-73.
7. Schneider EW, Johnson MW. Emerging
nonsurgical methods for the treatment of vitreomacular adhesion: a review. Clin
Ophthalmol. 2011; 5: 115165.
8. Johnson MW. Posterior vitreous detachment: evolution and complications
of its early stages. Am J Ophthalmol. 2010 Mar;
149 (3): 371-82.e1.
9. Stalmans P, Delaey C, de Smet MD, van Dijkman E, Pakola S. Intravitreal
injection of microplasmin for treatment of vitreomacular
adhesion: results of a prospective, randomized, sham-controlled phase II trial (the MIVI-IIT trial). Retina. 2010; 30 (7):
1122-7.
10. Benz MS, Packo KH, Gonzalez V, Pakola S, Bezner D, Haller JA, Schwartz SD. A placebo controlled trial of microplasmin intravitreous
injection to facilitate posterior vitreous
detachment before vitrectomy. Ophthalmology, 2010; 117 (4): 791-7.
11. Ruiz CQ, Pieramici DJ, Rabena M, Avery RL. Severe acute vision loss, dyschromatopsia, and
changes in the ellipsoid zone on SD-OCT associated with intravitreal
ocriplasmin injection. Retinal Cases and Brief Reports, 2015; 9 (2): 145-8.
12. Silva RA, Moshfeghi DM, Leng T. Retinal
breaks due to intravitreal ocriplasmin. Clin Ophthalmol. 2014; 8: 159194.
13. Hahn P, Chung MM, Flynn Jr HW, Huang SS, Kim JE,
Mahmoud TH, et al. Safety profile of ocriplasmin for symptomatic
vitreomacular adhesion: a comprehensive analysis
of premarketing and postmarketing experiences. Retina. 2015; 35 (6): 1128-34.
14. Varma R,
Haller
JA2, Kaiser PK3.
Improvement in Patient-Reported Visual Function after Ocriplasmin for Vitreomacular Adhesion: Results of
the Microplasmin for Intravitreous Injection-Traction Release Without Surgical Treatment (MIVI-TRUST) Trials.
JAMA Ophthalmol.
2015; 133 (9): 997-1004.
15. Stalmans P, Benz MS, Gandorfer A, Kampik A, Girach A,
Pakola S, et al. Enzymatic
vitreolysis with ocriplasmin for vitreomacular traction and macular holes. N Engl J Med. 2012 Aug. 16; 367 (7): 606-15.
16. Witkin AJ, Patron ME, Castro LC, Reichel E,
Rogers AH, Baumal CR, et al. Anatomic and visual outcomes of
vitrectomy for vitreomacular traction syndrome. Ophthalmic
Surg Lasers Imaging, 2010 Jul-Aug; 41 (4): 425-31.
17. McHugh D, Gupta B, Saeed M. Intravitreal gas
injection for the treatment of diabetic macular edema. Clin
Ophthalmol. 2011; 5: 154348.
18. Day S, Martinez JA, Nixon PA, Levitan M,
Dooner JW, Wong RW, et al.
Intravitreal sulfur hexafluoride
injection for the treatment of vitreomacular traction syndrome. Retina. 2016 Apr; 36 (4): 733-7.
19. Mori K, Saito S, Gehlbach PL, Yoneya S. Treatment of stage
2 macular hole by intravitreous injection
of expansile gas and induction of posterior vitreous detachment. Ophthalmology, 2007 Jan; 114 (1): 127-33.
20. Steinle N, Dhoot D, Pieramici DJ, See RF, Castellarin A, Couvillion S, et al.
Comparison of Three Non-surgical Treatments for Vitreomacular
Traction (VMT). Investigative ophthalmology
& visual science, 2016; 57 (12).
21. Claus MG,
Feron
E2, Veckeneer M2.
Pneumatic release of focal vitreomacular traction. Eye (Lond). 2017 Mar; 31 (3): 411-6.
22. Chan CK,
Lin
SG, Nuthi AS, Salib DM. Pneumatic retinopexy for the repair
of retinal detachments: a comprehensive review (1986-2007). Surv Ophthalmol.
2008 Sep-Oct; 53 (5): 443-78.
23. Chan CK, Crosson JN, Mein CE, Daher N. Pneumatic Vitreolysis for Relief of
Vitreomacular Traction. Retina, 2017 Oct; 37 (10): 1820-31.
24. Steinle N. Pointers for Performing Pneumatic VitreolysisHelpful
hints for the treatment of patients with symptomatic VMT. Retina Today; 2017
[cited 2017]; Available from:
http://retinatoday.com/2017/12/pointers-for-performing-pneumatic-vitreolysis.
25. Jackson T. Its a gas! Pneumatic release of VMT. Eye (Lond). 2017 Mar; 31 (3): 3478.